Courier Capital LLC Sells 546 Shares of Sanofi (NASDAQ:SNY)

Courier Capital LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 3.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,960 shares of the company’s stock after selling 546 shares during the quarter. Courier Capital LLC’s holdings in Sanofi were worth $824,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Rise Advisors LLC boosted its position in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Salem Investment Counselors Inc. bought a new stake in Sanofi in the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC lifted its position in Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares during the last quarter. Frazier Financial Advisors LLC bought a new stake in Sanofi in the 4th quarter worth approximately $28,000. Finally, McIlrath & Eck LLC lifted its position in Sanofi by 143.3% in the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after buying an additional 361 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $48.52 on Friday. The business has a 50 day moving average of $48.63 and a 200 day moving average of $48.55. The company has a market capitalization of $122.89 billion, a price-to-earnings ratio of 24.38, a PEG ratio of 1.49 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.96. The company had revenue of $11.36 billion during the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. On average, sell-side analysts predict that Sanofi will post 4.13 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.